Thiazolidinedione use is associated with reduced risk of Parkinson’s disease in patients with diabetes: a meta-analysis of real-world evidence

Background The thiazolidinedione (TZD) class of oral antidiabetic agents are used to treat type 2 diabetes mellitus (DM). This meta-analysis aimed to understand the protective effect of TZD on Parkinson’s disease (PD) in people with diabetes. Method A literature search was performed in PubMed, Embas...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Neurological sciences Ročník 41; číslo 12; s. 3697 - 3703
Hlavní autori: Hussain, Salman, Singh, Ambrish, Baxi, Harveen, Taylor, Bruce, Burgess, John, Antony, Benny
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: Cham Springer International Publishing 01.12.2020
Springer Nature B.V
Predmet:
Antidiabetics
Diabetes
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - drug therapy
Diabetes Mellitus, Type 2 - epidemiology
Humans
Hypoglycemic Agents - therapeutic use
Medicine
Medicine & Public Health
Meta-analysis
Movement disorders
Neurodegenerative diseases
Neurology
Neuroprotection
Neuroradiology
Neurosciences
Neurosurgery
Original Article
Parkinson Disease - drug therapy
Parkinson Disease - epidemiology
Parkinson's disease
Population studies
Proportional Hazards Models
Psychiatry
Systematic review
Thiazolidinediones - therapeutic use
Diabetes mellitus
Pioglitazone
Parkinson’s disease
Glitazone
Thiazolidinedione’s
Meta-analysis
ISSN:1590-1874, 1590-3478, 1590-3478
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Background The thiazolidinedione (TZD) class of oral antidiabetic agents are used to treat type 2 diabetes mellitus (DM). This meta-analysis aimed to understand the protective effect of TZD on Parkinson’s disease (PD) in people with diabetes. Method A literature search was performed in PubMed, Embase, and Cochrane central from inception to until 30 September 2019. We included all real-world evidence studies assessing the use of TZD class of drugs and the risk of PD in people with diabetes. Quality of the studies was evaluated using the Newcastle-Ottawa scale. The primary outcome was the pooled hazard ratio (HR) of PD among type 2 DM TZD users as compared with TZD non-users in people with diabetes. The secondary outcome was the HR of PD among type 2 DM TZD users as compared with non-users (include both diabetic and nondiabetic population). Meta-analysis was performed using RevMan software. Results Out of five studies selected for inclusion, four studies fulfilled the criteria for primary outcomes. The participants’ mean age and follow-up duration were 66.23 ± 9.59 years and 5.25 years (2.97–7.9 years), respectively. There was a significant reduction in the risk of PD (pooled adjusted HR of 0.81 [95% CI 0.70–0.93, p  = 0.004]) in TZD users compared with non-TZD users in people with diabetes. A significant protective effect of TZD was observed in Caucasian population (3 studies) (HR 0.78 (95% CI 0.66–0.92), p  = 0.003). Conclusion This meta-analysis demonstrates a potential neuroprotective effect of TZD for PD risk in the population with DM.
Bibliografia:ObjectType-Article-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-3
ObjectType-Evidence Based Healthcare-1
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ISSN:1590-1874
1590-3478
1590-3478
DOI:10.1007/s10072-020-04494-3